サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1594981

レポーター遺伝子アッセイの世界市場

Reporter Gene Assays

出版日
ページ情報
英文 88 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
レポーター遺伝子アッセイの世界市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 88 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポーター遺伝子アッセイの世界市場は2030年までに99億米ドルに到達

2023年に63億米ドルと推定されるレポーター遺伝子アッセイの世界市場は、分析期間2023-2030年にCAGR 6.7%で成長し、2030年には99億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるルシフェラーゼアッセイは、CAGR7.6％を記録し、分析期間終了までに41億米ドルに達すると予測されます。蛍光タンパク質関連アッセイ分野の成長率は、分析期間でCAGR 7.0％と推定されます。

米国市場は19億米ドルと推定、中国はCAGR6.2％で成長すると予測

米国のレポーター遺伝子アッセイ市場は2023年に19億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.1%と5.4%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界のレポーター遺伝子アッセイ市場- 主要動向と促進要因のまとめ

現代の調査でレポーター遺伝子アッセイが果たす役割とは？

レポーター遺伝子アッセイは、生物医学研究、遺伝学、薬剤開発の分野で極めて重要であり、遺伝子発現や細胞イベントをモニタリングするための不可欠なツールとして機能しています。これらのアッセイでは、容易に測定可能なタンパク質を産生する「レポーター」遺伝子が標的細胞に挿入されます。標的遺伝子やプロモーターが活性化されると、レポーター遺伝子もそのタンパク質を発現し、遺伝子活性の可視化や定量化が可能になります。この技術は、細胞経路、遺伝子発現動態、様々な疾患のメカニズムに関する貴重な洞察を研究者に提供します。レポーター遺伝子アッセイの需要は、信頼性が高く、効率的で、非侵襲的に細胞の挙動を観察する手段を提供し、科学者がリアルタイムで細胞応答をよりよく理解できるようにするため、著しく伸びています。分子生物学と遺伝学研究の急増を考えると、レポーター遺伝子アッセイは、特にがん生物学、神経生物学、免疫学などの用途において、研究に不可欠な要素になりつつあります。

さらに、レポーター遺伝子アッセイは創薬においても重要であり、潜在的な化合物の有効性や毒性を評価するために使用されています。製薬会社は、特定の細胞経路との相互作用をモニターすることによって有望な薬剤候補を同定するために、これらのアッセイに大きく依存しています。例えば、レポーターアッセイは、Gタンパク質共役受容体（GPCR）のような特定の受容体の活性化を測定することができます。レポーター遺伝子アッセイは、細胞レベルでの薬物活性に関するリアルタイムの洞察を提供することで、研究者が開発プロセスの早い段階で副作用を特定できるようになり、時間とリソースを節約できます。 このようにレポーター遺伝子アッセイは、基礎研究の推進と創薬パイプラインの強化という2つの役割を担っているため、さまざまな科学分野において貴重なツールとして位置づけられています。

技術の進歩はどのようにレポーター遺伝子アッセイを形成しているのでしょうか？

技術の進歩は、レポーター遺伝子アッセイの効率性、感度、適用性を著しく向上させています。例えば、生物発光や蛍光イメージングのようなイメージング技術の革新は、レポーター遺伝子の活性をより正確に可視化することを可能にしました。遺伝子発現に伴って光を発する生物発光アッセイは、高感度でバックグラウンドノイズが少ないため、遺伝子発現のより正確な測定を可能にし、人気を博しています。同様に、緑色蛍光タンパク質（GFP）のような蛍光レポーター遺伝子は、顕微鏡下で観察できる鮮やかな視覚的出力を生み出す能力により、広く採用されています。このようなイメージング技術の進歩は、研究者が遺伝子発現をより効果的に、リアルタイムで検出し定量化することを可能にし、レポーター遺伝子アッセイの利用方法を一変させました。

さらに、ハイスループット・スクリーニング技術の開発により、研究者は特に創薬においてレポーター遺伝子アッセイを用いた大規模な研究を行うことができるようになりました。ハイスループット・システムにより、何千もの化合物の迅速な試験が可能になり、特定の遺伝子や経路に対する影響を効率的に評価することができます。自動化されたシステムとデータ解析により、研究者は潜在的な創薬候補を迅速に特定し、創薬プロセスを加速することができます。さらに、CRISPR-Cas9テクノロジーとレポーター遺伝子アッセイの統合により、その応用範囲はさらに広がった。CRISPRベースの編集により、特定の遺伝子を正確に操作することが可能になり、レポーターアッセイを用いることで、研究者はこれらの遺伝子改変の効果を直接観察することができます。技術の進歩に伴い、レポーター遺伝子アッセイはさらに多用途で適応性が高く、ライフサイエンスにおける研究開発に不可欠なものとなっていくと思われます。

レポーター遺伝子アッセイに待ち受ける課題と機会とは？

調査における重要な役割にもかかわらず、レポーター遺伝子アッセイにはある限界と課題があります。一つの大きな課題は、細胞成分による干渉や"バックグラウンドノイズ "の可能性であり、これは時にアッセイ結果の正確性に影響を与えることがあります。天然に存在する酵素やタンパク質のような内因性の細胞因子がレポーターと反応し、真の結果を不明瞭にする偽陽性や偽陰性を作り出す可能性があります。この問題は、複雑な細胞タイプや複数遺伝子の相互作用を含むアッセイでは特に顕著で、細胞の不均一性がシグナルの解釈を複雑にする可能性があるからです。もう一つの課題は、調査を実施し解釈するために専門的な装置や技術的な専門知識が必要であることで、これはリソースを必要とし、小規模な研究室や研究機関にとっては障壁となりうる。

しかし、これらの課題は、レポーター遺伝子アッセイ市場にイノベーションの機会をもたらしています。例えば、より高い特異性と感度を持つアッセイに対する需要が高まっており、これが新規レポーター遺伝子や最適化されたアッセイフォーマットの開発を後押ししています。スプリットルシフェラーゼやスプリットGFPシステムなどのイノベーションは、特定の細胞間相互作用が起こったときにのみシグナルを発するレポータータンパク質を分離することによって、バックグラウンドノイズを減らし、アッセイの精度を高めることを目的としています。さらに、より多くの製薬会社や学術研究機関がレポーター遺伝子アッセイの価値を認識するにつれて、専門的なアッセイサービスを提供する開発業務受託機関（CRO）の市場も拡大しています。これらのCROは、レポーター遺伝子アッセイを実施するための専門知識と設備を提供し、研究機関が技術的、財政的な制約を克服することを可能にします。革新的なソリューションでこれらの課題に対処することで、レポーター遺伝子アッセイ市場は成長と進化を遂げ、現代の科学研究のニーズに応える態勢を整えています。

レポーター遺伝子アッセイ市場を加速する主な促進要因は何か？

レポーター遺伝子アッセイ市場の成長は、科学研究とバイオテクノロジーの進歩を反映するいくつかの要因によって牽引されています。がん、神経変性疾患、感染症などの疾病の有病率の増加が、疾病メカニズムの解明に役立つ精密な分子ツールに対する需要を煽っています。レポーター遺伝子アッセイは、特に遺伝子制御を理解することが効果的な治療に不可欠である腫瘍学や免疫学において、疾患経路を研究し治療戦略を開発するための貴重な方法を提供します。さらに、遺伝子研究の増加とCRISPR遺伝子編集技術の採用が需要を加速しています。研究者は、細胞機能に対する特定の遺伝子改変の影響を評価するためにレポーター遺伝子アッセイを頻繁に使用しています。CRISPR編集による遺伝子発現の変化をリアルタイムで観察できるレポーターアッセイは、このような最先端の研究に不可欠なものとなっています。

もう一つの主な推進力は、製薬会社と学術研究機関の双方による創薬研究開発への投資の拡大です。製薬業界が標的治療や精密医療への投資を拡大するにつれ、レポーター遺伝子アッセイのような信頼性が高く効率的な検査法に対する需要が急増しています。ハイスループットスクリーニング機能により、レポーターアッセイはよりスケーラブルになり、研究者は大規模な化合物ライブラリーを迅速にスクリーニングできるようになった。さらに、研究において3D細胞培養やオルガノイドモデルが使用されるようになり、複雑な生物学的システムで効果的に機能するレポーター遺伝子アッセイへのニーズが高まり、より生理学的に適切な結果が得られるようになりました。最後に、特に米国と欧州におけるライフサイエンス研究に対する政府の支援政策と資金援助が、市場をさらに押し上げています。これらの促進要因が相まって、レポーター遺伝子アッセイ市場を前進させ、生物医学・薬学研究におけるその継続的な重要性を確実なものにしています。

セグメント

タイプ（ルシフェラーゼアッセイ、蛍光タンパク質関連アッセイ、クロラムフェニコールアセチルトランスフェラーゼアッセイ、β-ガラクトシダーゼアッセイ、β-グルクロニダーゼアッセイ、その他のタイプ）、用途（臨床、in-vitro調査）、最終用途（製薬・バイオテクノロジー企業、CRO、学術・研究機関、病院・診断研究所）

調査対象企業の例（全32社）

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22700

Global Reporter Gene Assays Market to Reach US$9.9 Billion by 2030

The global market for Reporter Gene Assays estimated at US$6.3 Billion in the year 2023, is expected to reach US$9.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Luciferase Assays, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Fluorescent Protein-Related Assays segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 6.2% CAGR

The Reporter Gene Assays market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Reporter Gene Assay Market - Key Trends & Drivers Summarized

What Role Do Reporter Gene Assays Play in Modern Research?

Reporter gene assays are pivotal in the fields of biomedical research, genetics, and drug development, serving as essential tools for monitoring gene expression and cellular events. In these assays, a "reporter" gene, which produces an easily measurable protein, is inserted into a target cell. When the target gene or promoter is activated, the reporter gene also expresses its protein, making it possible to visualize or quantify gene activity. This technique provides researchers with valuable insights into cellular pathways, gene expression dynamics, and the mechanisms of various diseases. The demand for reporter gene assays has grown significantly as they provide a reliable, efficient, and non-invasive means to observe cellular behavior, allowing scientists to better understand cellular responses in real time. Given the surge in molecular biology and genetic research, reporter gene assays are becoming an indispensable component of research, particularly in applications such as cancer biology, neurobiology, and immunology.

Moreover, reporter gene assays are critical in drug discovery, where they are used to evaluate the efficacy and toxicity of potential drug compounds. Pharmaceutical companies rely heavily on these assays to identify promising drug candidates by monitoring their interactions with specific cellular pathways. For instance, reporter assays can measure the activation of certain receptors, such as G-protein coupled receptors (GPCRs), which are often targeted in drug development. By providing real-time insights into drug activity at a cellular level, reporter gene assays enable researchers to identify adverse effects early in the development process, saving time and resources. This dual role of reporter gene assays—advancing fundamental research and enhancing drug discovery pipelines—has positioned them as an invaluable tool across a range of scientific disciplines.

How Are Technological Advancements Shaping Reporter Gene Assays?

Technological advancements are significantly enhancing the efficiency, sensitivity, and applicability of reporter gene assays. For example, innovations in imaging techniques, such as bioluminescence and fluorescence imaging, have enabled more precise visualization of reporter gene activity. Bioluminescent assays, which produce light upon gene expression, have gained popularity for their high sensitivity and low background noise, allowing for more accurate measurements of gene expression. Similarly, fluorescent reporter genes, such as green fluorescent protein (GFP), have been widely adopted due to their ability to produce vivid visual outputs that can be observed under a microscope. These advancements in imaging technology have transformed how researchers utilize reporter gene assays, enabling them to detect and quantify gene expression more effectively and in real time.

Additionally, developments in high-throughput screening technology have allowed researchers to conduct large-scale studies using reporter gene assays, particularly in drug discovery. High-throughput systems enable rapid testing of thousands of compounds, making it possible to assess their effects on specific genes or pathways efficiently. With automated systems and data analytics, researchers can quickly identify potential drug candidates, accelerating the discovery process. Moreover, the integration of CRISPR-Cas9 technology with reporter gene assays has further expanded their applications. CRISPR-based editing allows for precise manipulation of specific genes, and by using reporter assays, researchers can directly observe the effects of these genetic modifications. As technology advances, reporter gene assays are likely to become even more versatile, adaptable, and integral to research and development in life sciences.

What Challenges and Opportunities Lie Ahead for Reporter Gene Assays?

Despite their critical role in research, reporter gene assays face certain limitations and challenges. One major challenge is the potential for interference or “background noise” from cellular components, which can sometimes affect the accuracy of assay results. Endogenous cellular factors, such as naturally occurring enzymes or proteins, may react with the reporter, creating false positives or negatives that obscure the true results. This problem is particularly pronounced in assays involving complex cell types or multi-gene interactions, as cellular heterogeneity can complicate signal interpretation. Another challenge is the need for specialized equipment and technical expertise to conduct and interpret reporter gene assays, which can be resource-intensive and may pose a barrier for smaller research labs or institutions.

However, these challenges also bring opportunities for innovation within the reporter gene assay market. For instance, there is growing demand for assays with higher specificity and sensitivity, which has driven the development of novel reporter genes and optimized assay formats. Innovations such as split-luciferase and split-GFP systems aim to reduce background noise and increase assay accuracy by separating reporter proteins that only emit a signal when specific cellular interactions occur. Additionally, as more pharmaceutical companies and academic research institutions recognize the value of reporter gene assays, the market for contract research organizations (CROs) offering specialized assay services is expanding. These CROs provide expertise and equipment for conducting reporter gene assays, allowing institutions to overcome technical and financial limitations. By addressing these challenges with innovative solutions, the reporter gene assay market is poised to grow and evolve, meeting the needs of modern scientific research.

What Are the Key Drivers Accelerating the Reporter Gene Assay Market?

The growth in the reporter gene assay market is driven by several factors that reflect advancements in scientific research and biotechnology. The increasing prevalence of diseases such as cancer, neurodegenerative disorders, and infectious diseases has fueled the demand for precise molecular tools that can help decode disease mechanisms. Reporter gene assays provide an invaluable method for studying disease pathways and developing therapeutic strategies, particularly in oncology and immunology, where understanding gene regulation is crucial for effective treatment. Furthermore, the rise in genetic research and the adoption of CRISPR gene editing technology have accelerated demand, as researchers frequently use reporter gene assays to assess the impact of specific genetic modifications on cellular functions. The ability to observe real-time changes in gene expression due to CRISPR edits has made reporter assays indispensable in these advanced studies.

Another key driver is the expanding investment in drug discovery and development by both pharmaceutical companies and academic research institutions. As the pharmaceutical industry invests more in targeted therapies and precision medicine, the demand for reliable and efficient testing methods like reporter gene assays has surged. High-throughput screening capabilities have made reporter assays more scalable, allowing researchers to screen large compound libraries quickly. Additionally, the increased use of 3D cell cultures and organoid models in research has led to a growing need for reporter gene assays that can work effectively in complex biological systems, enabling more physiologically relevant results. Finally, supportive government policies and funding for life sciences research, particularly in the United States and Europe, have further boosted the market. Together, these drivers are propelling the reporter gene assay market forward, ensuring its ongoing importance in biomedical and pharmaceutical research.

SCOPE OF STUDY:

The report analyzes the Reporter Gene Assays market in terms of US$ Million by the following Application; End-Use; Type, and Geographic Regions/Countries:

Segments:

Type (Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays, Other Types); Application (Clinical, In-Vitro Studies); End-Use (Pharma & Biotech Companies, Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Abcam PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biotium
  • Danaher Corporation
  • Genecopoeia, Inc.
  • Geno Technology, Inc.
  • Invivogen
  • Merck KGaA
  • Perkinelmer
  • Promega Corporation
  • Promocell
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Reporter Gene Assays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for High-throughput Screening Drives Adoption of Advanced Reporter Gene Assay Technologies
    • Growing Emphasis on Precision Medicine Strengthens Demand for Reporter Gene Assays in Drug Development
    • Rise in Gene Therapy Research Expands Addressable Market for Reporter Gene Assay Applications
    • Advancements in CRISPR and Gene Editing Technologies Propel Growth of Reporter Gene Assays for Target Validation
    • Increasing Focus on Cancer Research Spurs Demand for Reporter Gene Assays in Oncology Studies
    • Expansion of Cell-based Assays for Drug Discovery Drives Adoption of Reporter Gene Assay Tools
    • Growing Integration of Reporter Gene Assays in High-content Screening Expands Opportunities in Complex Studies
    • Technological Innovations in Bioluminescent and Fluorescent Reporters Enhance Sensitivity and Market Demand
    • Adoption of 3D Cell Culture Systems and Organoids Drives Demand for Compatible Reporter Gene Assay Solutions
    • Increasing Need for Real-time Gene Expression Monitoring in Research Boosts Market for Dynamic Reporter Assays
    • Rising Investments in Biotechnology and Pharmaceutical R&D Spur Growth in the Reporter Gene Assay Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Reporter Gene Assays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Luciferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Luciferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Fluorescent Protein-Related Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Fluorescent Protein-Related Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chloramphenicol Acetyltransferase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Chloramphenicol Acetyltransferase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Beta-Galactosidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Beta-Galactosidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Beta-Glucuronidase Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Beta-Glucuronidase Assays by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for In-Vitro Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for In-Vitro Studies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World 7-Year Perspective for Hospital & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 28: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • JAPAN
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • CHINA
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 46: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • EUROPE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for Reporter Gene Assays by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • FRANCE
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 60: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: France 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • GERMANY
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Germany 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ITALY
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Italy 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • UNITED KINGDOM
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 78: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 83: UK 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Reporter Gene Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Type - Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for Reporter Gene Assays by Type - Percentage Breakdown of Value Revenues for Luciferase Assays, Fluorescent Protein-Related Assays, Chloramphenicol Acetyltransferase Assays, Beta-Galactosidase Assays, Beta-Glucuronidase Assays and Other Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by Application - Clinical and In-Vitro Studies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for Reporter Gene Assays by Application - Percentage Breakdown of Value Revenues for Clinical and In-Vitro Studies for the Years 2024 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Reporter Gene Assays by End-Use - Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 101: Rest of World 7-Year Perspective for Reporter Gene Assays by End-Use - Percentage Breakdown of Value Revenues for Contract Research Organizations (CROs), Academic & Research Institutes, Hospital & Diagnostic Laboratories and Pharma & Biotech Companies for the Years 2024 & 2030

IV. COMPETITION